Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,024 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05749042 | A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma | unknown | Phase 2 | 70 | Xin-Hua XuOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05745597 | Prognostic Study of HPV Virus Integration in Women With HSIL | unknown | — | 1,000 | Fujian Maternity and Child Health HospitalOTHER | 1 | Feb 27, 2023 |
| NCT05740774 | Surgical Margin Assessment by 3D Ultrasound | unknown | N/A | 7 | Rigshospitalet, DenmarkOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT04929067 | Efficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma: a Phase II Clinical Trial | unknown | Phase 2 | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT05718167 | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | unknown | Phase 3 | 570 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT04839731 | Combination 5-FU / Calcipotriene Cream for SCCIS/SCC | unknown | Early Phase 1 | 30 | Carilion ClinicOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT04359199 | QUantitative Assessment of Swallowing After Radiation (QUASAR)(QUASAR) | unknown | — | 42 | Loren Mell, MDOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT02025036 | Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer(CRTCOESC) | unknown | Phase 3 | 249 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05578170 | Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma(PROBES) | unknown | — | 47 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT04704908 | Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m) | unknown | — | 979 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT04969445 | The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female | unknown | — | 647 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05045755 | The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female | unknown | — | 1,339 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05650216 | Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT） | unknown | Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05636150 | A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 48 | Peking Union Medical College HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05633641 | Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma | unknown | — | 60 | Fudan UniversityOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05386056 | Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 54 | Peking UniversityOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05596890 | Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients(PICCRT) | unknown | Phase 2 | 50 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT01855451 | Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma(HPVOropharynx) | unknown | Phase 3 | 189 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Nov 18, 2022 | clinicaltrials |
| NCT05143268 | Acupuncture for Dysphagia in Head and Neck Squamous Cell Carcinoma(ACP-HN) | unknown | — | 90 | Lorenzo LiviOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05611463 | Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients(CHANCE) | unknown | Phase 2 | 25 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05580341 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | unknown | Phase 3 | 1,200 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT03817307 | Validation of USPIO-enhanced MRI for Detection of Lymph Node Metastases in Head and Neck Carcinoma(USPIO-NECK) | unknown | N/A | 25 | Radboud University Medical CenterOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT04803331 | SPIO-enhanced MRI in Oral Cancer for Sentinel Lymph Node Identification(MAG-NODE) | unknown | N/A | 10 | Radboud University Medical CenterOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05594914 | AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 47 | The First Affiliated Hospital of University of South ChinaOTHER | 0 | Oct 26, 2022 | clinicaltrials |
| NCT05027204 | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | unknown | Phase 1 / Phase 2 | 94 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05038657 | Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).(AURORA) | unknown | Phase 2 | 36 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05561699 | Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer(SPEED) | unknown | N/A | 66 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT05024383 | Dissecting the Heterogeneity of Oral Cancer Pain | unknown | N/A | 80 | NYU College of DentistryOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05552651 | Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 40 | Tao JiangOTHER | 0 | Sep 23, 2022 | clinicaltrials |
| NCT05552807 | SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 | 120 | Sinocelltech Ltd.INDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05541445 | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05536843 | Clinical, Translational and Biomarker-Based Female Genital HPV Induced Dysplasia and Cancer Screening Study Using Cf-HPV-DNA Blood Tests(TTMV HPV DNA) | unknown | — | 500 | University of Mississippi Medical CenterOTHER | 0 | Sep 13, 2022 | clinicaltrials |
| NCT05522894 | AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC | unknown | Phase 2 | 80 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 31, 2022 | clinicaltrials |
| NCT04699994 | Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel | unknown | Phase 2 | 60 | Keio UniversityOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05170256 | Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients(HERES) | unknown | Phase 2 | 24 | Morten Mau-SørensenOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT05488860 | Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases | unknown | N/A | 20 | Xiangya Hospital of Central South UniversityOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05476965 | Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma(iCSDeR) | unknown | Phase 2 | 20 | Hubei Cancer HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05469061 | Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC | unknown | Phase 2 | 17 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT03946969 | Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT05449483 | Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05351762 | Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC | unknown | Phase 2 | 55 | Xijing HospitalOTHER | 0 | Jul 5, 2022 | clinicaltrials |
| NCT05426850 | ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma | unknown | — | 100 | Fudan UniversityOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05238363 | The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT05213312 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | unknown | Phase 2 / Phase 3 | 90 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04215471 | NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma(NATION1907II) | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03947775 | HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL | unknown | Phase 2 | 228 | University Health Network, TorontoOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT05409365 | Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris | unknown | — | 50 | Sohag UniversityOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT03623737 | Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC | unknown | Phase 2 / Phase 3 | 248 | National Taiwan University HospitalOTHER | 1 | Jun 7, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 1, 2023source: clinicaltrials